Does Asprin And Extended Release Dipyridamole Interact with Regadenoson?
CDI records a major classification for Asprin And Extended Release Dipyridamole and Regadenoson. The stored summary is: Dipyridamole increases cardiovascular effects of regadenoson. Risk of cardiovascular side effects may be increased if dipyridamole is not held 48 hours prior to stress testing. The mechanism involves dipyridamole potentiates adenosine a2a-receptor agonist effects. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Asprin And Extended Release Dipyridamole Class
- Nonsteroidal Anti-inflammatory Drug
- Regadenoson Class
- Adenosine Receptor Agonist
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Dipyridamole potentiates adenosine A2A-receptor agonist effects
What To Tell Your Doctor or Pharmacist
If you are taking Asprin And Extended Release Dipyridamole and your doctor is considering prescribing Regadenoson (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider